Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia

This clinical brief is supported by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health care economic analysis carrying out responsibilities for the selection for the selection of drugs for coverage, reimbursement, or other population-based health care management.

This article describes the efficacy and safety of a first-in-class treatment for adults with schizophrenia.